Original Article

You have free access to this content

Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease

A Phase 2 Trial

  1. Nitin Jain MD1,
  2. James M. Reuben PhD2,
  3. Hagop Kantarjian MD1,
  4. Changping Li MD2,
  5. Hui Gao PhD2,
  6. Bang-Ning Lee PhD2,
  7. Evan N. Cohen BS2,
  8. Theresa Ebarb RN1,
  9. David A. Scheinberg MD, PhD3,
  10. Jorge Cortes MD1,†,*

Article first published online: 17 JUN 2009

DOI: 10.1002/cncr.24468

Issue

Cancer

Cancer

Volume 115, Issue 17, pages 3924–3934, 1 September 2009

Additional Information

How to Cite

Jain, N., Reuben, J. M., Kantarjian, H., Li, C., Gao, H., Lee, B.-N., Cohen, E. N., Ebarb, T., Scheinberg, D. A. and Cortes, J. (2009), Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease. Cancer, 115: 3924–3934. doi: 10.1002/cncr.24468

Author Information

  1. 1

    Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  2. 2

    Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  3. 3

    Molecular Pharmacology and Chemistry Program and Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, New York

  1. †

    Fax: (713) 794-4297

*Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030

Publication History

  1. Issue published online: 20 AUG 2009
  2. Article first published online: 17 JUN 2009
  3. Manuscript Accepted: 3 FEB 2009
  4. Manuscript Revised: 29 JAN 2009
  5. Manuscript Received: 16 DEC 2008

Funded by

  • National Institute of Health. Grant Number: PO1 CA23766

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (278K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Matthew Vanneman, Glenn Dranoff, Combining immunotherapy and targeted therapies in cancer treatment, Nature Reviews Cancer, 2012, 12, 4, 237

    CrossRef

  2. 2
    Maria Karvela, G Vignir Helgason, Tessa L Holyoake, Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia, Expert Review of Anticancer Therapy, 2012, 12, 3, 381

    CrossRef

  3. 3
    R Casalegno-Garduño, A Schmitt, M Schmitt, Clinical peptide vaccination trials for leukemia patients, Expert Review of Vaccines, 2011, 10, 6, 785

    CrossRef

  4. 4
    Christopher S. Hourigan, Hyam I. Levitsky, Evaluation of Current Cancer Immunotherapy, The Cancer Journal, 2011, 17, 5, 309

    CrossRef

  5. 5
    Marie Bleakley, Stanley R Riddell, Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia, Immunology and Cell Biology, 2011, 89, 3, 396

    CrossRef

  6. 6
    Paolo Gallipoli, Sheela A. Abraham, Tessa L. Holyoake, Hurdles Toward a Cure for CML: The CML Stem Cell, Hematology/Oncology Clinics of North America, 2011, 25, 5, 951

    CrossRef

  7. 7
    K. Rezvani, Peptide vaccine therapy for leukemia, International Journal of Hematology, 2011, 93, 3, 274

    CrossRef

  8. 8
    Gheath Alatrash, Jeffrey J Molldrem, Vaccines as consolidation therapy for myeloid leukemia, Expert Review of Hematology, 2011, 4, 1, 37

    CrossRef

  9. 9
    Monica Bocchia, Marzia Defina, Lara Aprile, Micaela Ippoliti, Rosaria Crupi, Michela Rondoni, Alessandro Gozzetti, Francesco Lauria, Complete molecular response in CML after p210 BCR–ABL1-derived peptide vaccination, Nature Reviews Clinical Oncology, 2010, 7, 10, 600

    CrossRef

  10. 10
    Vladimír Vonka, Immunotherapy of chronic myeloid leukemia: present state and future prospects, Immunotherapy, 2010, 2, 2, 227

    CrossRef

  11. You have free access to this content11
    Massimo Breccia, Monica Bocchia, Laura Cannella, Marzia Defina, Micaela Ippoliti, Giuseppina Loglisci, Michelina Santopietro, Francesco Lauria, Giuliana Alimena, Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance, British Journal of Haematology, 2010, 150, 2
    Direct Link:
  12. 12
    Deepika Kanojia, Manoj Garg, Shikha Saini, Sumit Agarwal, Rajive Kumar, Anil Suri, Sperm associated antigen 9 expression and humoral response in chronic myeloid leukemia, Leukemia Research, 2010, 34, 7, 858

    CrossRef

  13. 13
    Alfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes, Third-Generation Tyrosine Kinase Inhibitors and Beyond, Seminars in Hematology, 2010, 47, 4, 371

    CrossRef

  14. 14
    Taylor H. Schreiber, Luis Raez, Joseph D. Rosenblatt, Eckhard R. Podack, Tumor immunogenicity and responsiveness to cancer vaccine therapy: The state of the art, Seminars in Immunology, 2010, 22, 3, 105

    CrossRef

  15. 15
    Carmen Fava, Jorge E. Cortés, Hagop Kantarjian, Elias Jabbour, Standard Management of Patients With Chronic Myeloid Leukemia, Clinical Lymphoma, Myeloma & Leukemia, 2009, 9, 0, S382

    CrossRef

  16. 16
    Elias Jabbour, Jorge Cortes, Hagop Kantarjian, Standard Management of Patients with Chronic Myeloid Leukemia,
    Direct Link:
View Full Article (HTML) Get PDF (278K)